ProHealth.com
July 26, 2008
This long-term Phase III trial is recruiting adults ages 18 to 50 of both genders meeting diagnostic criteria for ADHD. Study title: “A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD),” Clinicaltrials.gov # NCT00700427.
Patients will first all receive drug atomoxetine for 12 weeks. Then those meeting the response criteria will be assigned randomly to the drug or a placebo (neither patients nor investigators will know who is taking which) for up to 37 weeks.
Trial sites are located in 29 states - Hawaii to Vermont - Puerto Rico, 6 Canadian provinces, and 16 other countries.
Atomoxetine is a non-stimulant drug manufactured by Eli Lilly. It is a selective norepinephrine reuptake inhibitor which increases levels of natural norepinephrine in the brain, and is FDA approved for treating ADHD.
Purpose – to measure proportion of patients who maintain satisfactory response and change in ADHD quality of life scores over a period of up to 1 year, and to measure number of days to relapse after stopping medication. Safety is not designated as an issue.
To review the list of 150 study center locations, see the Clinical Trials.gov listing for http://clinicaltrials.gov/ct2/show/NCT00700427.
For details call the Lilly Call Center (1-877-285-4559 or 1-317-615-4559)- Accepting calls only Mon-Fri, 9 am to 5 pm, Eastern US Time Zone.
|
